Sign in
Shelby Hill

Shelby Hill

Research Analyst at RBC Capital Markets, LLC

New York, NY, US

Shelby Hill is an equity research analyst at RBC Capital Markets, specializing in coverage of the biotechnology sector with a particular focus on companies such as Ultragenyx Pharmaceutical Inc. Hill's research contributions have included participation in earnings calls and providing company-specific analysis, reflecting specialized insight within the life sciences industry. While publicly available records indicate activity dating to at least 2025 and research engagement at RBC, further details on career timeline, historical performance metrics, and professional credentials have not been widely published. Hill’s ongoing coverage contributes to market understanding for targeted biopharma clients.

Shelby Hill's questions to Ultragenyx Pharmaceutical (RARE) leadership

Question · Q2 2025

On behalf of Luca Eci from RBC Capital Markets, Shelby Hill asked for more color on the Sanfilippo CRL, referencing prior comments about shipping validation and a stringent inspector, and questioned if the FDA was 'missing the forest for the trees.'

Answer

Emil Kakkis, Founder, President & CEO, responded that it is the FDA's job to scrutinize details ('check every tree') and that CMC rigor is essential. He emphasized that the company's focus is on methodically addressing all the issues raised in the CRL, which they believe are entirely manageable, rather than dwelling on the inspection process.

Ask follow-up questions

Fintool

Fintool can predict Ultragenyx Pharmaceutical logo RARE's earnings beat/miss a week before the call

Let Fintool AI Agent track Shelby Hill for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free